Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.
Ruth He, MD: With the approval of the combination of bevacizumab and atezolizumab in the frontline treatment, there are no randomized clinical trial data on how to sequence the subsequent lines of therapy for HCC [hepatocellular carcinoma]. There are small retrospective studies and data on subsequent treatment in patients enrolled in frontline settings, which suggest the benefit of subsequent therapies, including additional immune checkpoint inhibitors or tyrosine kinase inhibitors.
Given the benefit of subsequent lines of therapy in HCC, I believe appropriate evaluation for initiation of systemic therapy and transition into systemic therapy most likely will provide an improved outcome in HCC patients.
Transcript edited for clarity.